Lifecore Biomedical
LFCR
91 hedge funds and large institutions have $325M invested in Lifecore Biomedical in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 36 reducing their positions, and 11 closing their positions.
0.13% more ownership
Funds ownership: 93.8% → 93.93% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $334M → $325M (-$8.77M)
4% less funds holding
Funds holding: 95 → 91 (-4)
31% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 36
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$2.19M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$2.03M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.41M |
| 4 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
+$933K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$404K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Algert Global
San Francisco,
California
|
-$1.43M |
| 2 |
WC
Walthausen & Co
Malta,
New York
|
-$1.37M |
| 3 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$994K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$968K |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$734K |
LFCR Hedge Fund Activity: Q4 2017 in Review
91 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2017, worth a combined $325M — down 2.6% from $334M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LFCR and 7 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 25 added.
The largest buyer was Russell Investments Group, adding an estimated $2.19M. The largest seller was Algert Global, cutting an estimated $1.43M.
- 91 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2017, down from 95 in Q3 2017.
- Funds reported $325M of Lifecore Biomedical stock for Q4 2017, down 2.6% quarter-over-quarter.
- 7 funds opened new Lifecore Biomedical positions in Q4 2017 and 11 closed out, a net change of -4 holders.
- The largest Lifecore Biomedical buyer in Q4 2017 was Russell Investments Group, an estimated $2.19M added.
- The largest Lifecore Biomedical seller in Q4 2017 was Algert Global, an estimated $1.43M sold.
Based on aggregated 13F filings for Q4 2017.